Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons
© Lambert et al; licensee BioMed Central Ltd. 2011
Received: 26 October 2010
Accepted: 13 January 2011
Published: 13 January 2011
Brimonidine is a common drug for lowering ocular pressure and may directly protect retinal ganglion cells in glaucoma. The disease involves early loss of retinal ganglion cell transport to brain targets followed by axonal and somatic degeneration. We examined whether brimonidine preserves ganglion cell axonal transport and abates degeneration in rats with elevated ocular pressure induced by laser cauterization of the episcleral veins.
Ocular pressure was elevated unilaterally by 90% for a period of 8 weeks post- cauterization. During this time, brimonidine (1mg/kg/day) or vehicle (phosphate-buffered saline) was delivered systemically and continuously via subcutaneous pump. Animals received bilateral intravitreal injections of fluorescent cholera toxin subunit β (CTB) two days before sacrifice to assess anterograde transport. In retinas from the vehicle group, elevated pressure induced a 44% decrease in the fraction of ganglion cells with intact uptake of CTB and a 14-42% reduction in the number of immuno-labelled ganglion cell bodies, with the worst loss occurring nasally. Elevated pressure also caused a 33% loss of ganglion cell axons in vehicle optic nerves and a 70% decrease in CTB transport to the superior colliculus. Each of these components of ganglion cell degeneration was either prevented or significantly reduced in the brimonidine treatment group.
Continuous and systemic treatment with brimonidine by subcutaneous injection significantly improved retinal ganglion cell survival with exposure to elevated ocular pressure. This effect was most striking in the nasal region of the retina. Brimonidine treatment also preserved ganglion cell axon morphology, sampling density and total number in the optic nerve with elevated pressure. Consistent with improved outcome in the optic projection, brimonidine also significantly reduced the deficits in axonal transport to the superior colliculus associated with elevated ocular pressure. As transport deficits to and from retinal ganglion cell projection targets in the brain are relevant to the progression of glaucoma, the ability of brimonidine to preserve optic nerve axons and active transport suggests its neuroprotective effects are relevant not only at the cell body, but throughout the entire optic projection.
Glaucoma is a chronic disease that causes vision loss through the degeneration of retinal ganglion cell (RGC) neurons and their axons in the optic nerve [1, 2]. While age is an important risk factor, the only modifiable risk factor and sole target for clinical intervention is elevated intraocular pressure (IOP) or ocular hypertension (OHT) . Lowering IOP generally slows progression in glaucoma , but does not necessarily stop degeneration . Thus, there is great interest in identifying neuroprotective agents as potential therapies [5, 6].
Brimonidine (BMD; UK14304, Alphagan) is a non-selective α2-adrenergic receptor agonist currently used as a treatment to lower IOP in glaucoma. An effect of BMD is to decrease aqueous humor production by inhibition of adenylate cyclase inhibition, which lowers cAMP levels . The drug also increases uveoscleral outflow due to prostaglandin release and/or ciliary muscle relaxation . Independent of its IOP-lowering properties, BMD is neuroprotective for RGCs in various injury models [9–13]. Potential mechanisms underlying these effects include the inhibition of glutamate release, regulation of calcium influx in the inner retina, modulation of NMDA receptor signalling in RGCs, and upregulation of trophic factor expression [14–16]. Because of its dual action to lower IOP and perhaps protect against neuronal injury, BMD may hold promise in the treatment of glaucoma and other optic neuropathies .
Following acute ischemic injury, BMD preserves axonal transport along RGC axons from the retina to the superior colliculus . This is intriguing in the context of glaucoma, as recent evidence indicates axon-specific mechanisms play an early role in the pathology of the disease [19–21]. Here we investigated whether systemic treatment with BMD by continuous subcutaneous injection improves axon survival in the optic nerve and anterograde transport to the colliculus with acute OHT.
Systemic brimonidine treatment does not affect IOP
Brimonidine prevents loss of RGCs with OHT
For all retinal quadrants, the density of SMI31+ RGCs in the control retinas peaked within 1-2 mm of the optic nerve head (3,400 to 5,400 RGCs/mm2) and decreased slightly (17 to 18%) at 4 mm out (Figure 4). In the superior retina of the vehicle group, OHT decreased RGC density by 15 to 17% across eccentricity compared to control eyes. RGC density in the same sector for the BMD OHT retinas was 14 - 24% higher than the vehicle OHT retinas; neither group was significant different than the corresponding control eye (p ≥ 0.2). In the inferior quadrant of vehicle retinas, OHT decreased RGC density 14 - 25% compared to control retinas with significant reductions of 25% and 23% observed at 1 and 2mm eccentric, respectively (p ≤ 0.05). For the BMD group in this quadrant, RGC density did not change with OHT compared to control (p ≥ 0.25). In the temporal quadrant for vehicle retinas, OHT decreased RGC density 14 - 27% compared to control; at 4mm eccentricity this decrease (27%) was significant (p = 0.04). For the BMD group in this quadrant, RGC density in OHT retinas was similar to control retinas at all eccentricities (p ≥ 0.2). The 31% improvement in RGC density compared to vehicle OHT retinas was significant at 1 mm from the optic disc (p = 0.05). Finally, RGC loss in vehicle OHT eyes was most dramatic in the nasal retina, where RGC density decreased at every location. Decreased density compared to control retinas ranged from 42% nearest the optic disc to 26% at 4 mm eccentricity (p ≤ 0.02). BMD treatment afforded partial rescue of RGCs in this quadrant, with significant increases of 30-42% at 1-3 mm eccentricity compared to vehicle OHT retinas (p ≤ 0.005). However, only at 1 mm was RGC density in the BMD OHT group comparable to the control group (p = 0.09).
Brimonidine protects RGC axons
Brimonidine substantially restores anterograde transport
In this study, we quantified how systemic delivery of BMD via subcutaneous osmotic pump protected RGCs challenged by elevated IOP in a rat model of OHT. In the absence of treatment, OHT for 8 weeks induced pathology at several levels. In the vehicle group, the worst OHT-related outcome was 70% depletion in transport of CTB to the superior colliculus (Figure 6). This deficit cannot be accounted for entirely by loss of active uptake of CTB by RGCs in the retina, which was reduced by only 44% (Figure 3). Depletion of transport was followed by a 33% loss of axons in the optic nerve (Figure 5) and finally by an average decrease in RGC somatic density of about 16% as measured by SMI31 labelling (Figure 4). In the retina, OHT was also associated with severely dystrophic axons, swollen RGC somas, and the accumulation of phosphorylated neurofilaments in dendrites (Figure 2).
These results support an OHT-induced progression in which a functional deficit precedes structural pathology. Loss of active uptake and transport of CTB was far worse than axon loss in the optic nerve, which in turn was worse than RGC somatic drop-out in the retina. This progression is similar to that described in the DBA2J mouse model of glaucoma [20, 21, 23]. Interestingly, RGC somatic loss as measured by SMI31 labelling was not uniform. Rather, it was worst in the nasal retina, where OHT decreased RGC density 26 to 42% across eccentricities (Figure 4). This spatial progression too is consistent with the sectorial pattern of RGC pathology observed in other glaucoma models [22, 23, 29, 30]. Though axonal transport to the superior colliculus was severely affected by OHT, our retinotopic maps also hint of sectorial progression (Figure 7; ).
Although there is some earlier evidence that BMD can preserve optic nerve axons and RGC axonal transport after acute injury [9, 31, 32], previous studies of BMD's effect in glaucoma models have focused on retinal outcomes [11, 12, 16, 33, 34]. Following episcleral vein cautery, BMD delivered via intraperitoneal injection prevented OHT-induced loss of RGC cell bodies labelled by retrograde transport of FluoroGold from the colliculus [12, 33]. In studies similar to ours in which OHT was induced by laser photocoagulation of episcleral and limbal veins for 3 weeks, BMD delivered by subcutaneous pump also improved the number of RGCs labeled retrogradely [11, 16, 34]. Our results are in agreement with these previous studies in that systemic BMD delivery increased RGC cell body survival (Figure 3 and Figure 4), even for our much longer period of OHT. However, given recent evidence that RGC somatic loss occurs late in disease progression , we examined axonal transport to the colliculus and axon survival in the nerve, both of which are challenged much earlier .
We found that systemic BMD treatment via subcutaneous delivery ameliorated the effects of OHT on each of our outcome measures. In the retina, BMD preserved RGC axonal and dendritic morphology (Figure 2), restored CTB uptake (Figure 3), and increased the number of SMI31+ RGCs, especially in the nasal retina where OHT-induced loss was greatest (Figure 4). In the optic nerve, BMD restored the axonal population to control levels as well (Figure 5). Finally, BMD improved anterograde axonal transport to the SC by 124% (Figure 6). As transport deficits to and from RGC targets are relevant to the progression of glaucoma [20, 21], the ability of BMD to preserve optic nerve axons and axonal transport suggest its neuroprotective effects are pertinent not only at RGC soma, but throughout the entire retinal projection.
BMD is a non-subtype-selective α2-adrenergic receptor agonist. All three α2 receptors subtypes are expressed in the retina, with expression of α2A and α2B receptors by RGCs and α2B receptors by glia [35, 36]. Activation of α2 receptors within the retina elicits many responses including reduced glial activation [11, 37], decreased oxidative stress [38, 39] and protection against apoptosis [40–42]. In addition, BMD may protect RGCs by regulating intracellular Ca2+ levels and glutamate availability within the retina [16, 43]. Excess glutamate can result in RGC apoptosis via overstimulation of NMDA receptors and subsequent increases in intracellular Ca2+. Stimulation of α2 receptors also results in the activation of the phosphatidylinositol 3 kinase (PI3K) pathway [44, 45]. Activation of the PI3K pathway promotes RGC survival after various injuries [46, 47], perhaps by altering gene expression [48–50], regulating protein activity [51, 52], or by affecting cellular metabolism [53, 54]. These and other responses make α2 agonists like BMD ideal neuroprotective agents within the retina.
A potential mechanism underling the neuroprotective effect of BMD on RGC axons involves the inactivation of glycogen synthase kinase-3 (GSK3) via the PI3K pathway. GSK3 is a constitutively active and ubiquitous kinase. In neurons, GSK3 phosphorylates microtubule-associated protein 1B, resulting in loss of stable microtubules . GSK3 also phosphorylates collapsin response mediator protein-2, which promotes microtubule assembly and links tubulin heterodimers to kinesin-1 to regulate protein transport to distal regions of axons [56–58]. Also, GSK3 activation is implicated in hyper-phosphorylation of axon cytoskeletal proteins, including neurofilaments [59, 60]. Interestingly, GSK3 can be inactivated by downstream kinases in the PI3K pathway [61–63], thus providing a possible link between α2 receptor activation and preservation of the axonal cytoskeleton. Activation of the PI3K pathway via treatment with BMD could counteract these changes, consequently preserving both axonal transport and structure. Since BMD applied either topically to the cornea or via systemic injection reaches the posterior segment in appreciable concentrations , its use could represent a viable intervention for combating early axon deficits in glaucoma.
Ocular hypertension in rats resulted in a substantial decline in RGC axonal transport to the superior colliculus, diminished axon survival in the optic nerve, and reduced RGC density in the retina, especially in the nasal quadrant. Systemic treatment with BMD significantly improved axonal transport and survival and either prevented or decreased loss of RGC density across retinal quadrants. As transport deficits to and from RGC targets are relevant to the progression of glaucoma, the ability of BMD to preserve optic nerve axons and axonal transport suggest its neuroprotective effects are pertinent not only at the cell body, but throughout the entire retinal projection as well.
IOP elevation and brimonidine delivery
Unilateral IOP elevation in male Sprague-Dawley rats (weight range, 350 - 400 g) was achieved by laser photocoagulation of episcleral and limbal veins as described previously . Rats were anesthetized with a mixture of ketamine (50 mg/kg), acepromazine (1 mg/kg), and xylazine (25 mg/kg) and two laser treatments were performed 1 week apart in order to achieve persistent IOP elevation. IOP was measured with a tonometer (TonoLab; Colonial Medical Supply, Franconia, NH). BMD (1 mg/kg/day) or vehicle phosphate-buffered saline (PBS) was administered systemically and continuously using an osmotic pump (Alzet; Durect, Cupertino, CA) inserted subcutaneously on the back of 16 animals per group. This concentration and mode of delivery was based on earlier results comparing 0.5 mg/kg/day vs. 1 mg/kg/day for efficacy in protecting RGC cell bodies during OHT . Treatment began at the time of initial IOP elevation and continued for 8 weeks. Age-matched naïve control rats (n = 16) were also included for comparison.
Cholera toxin β injection and tissue preparation
Forty-eight hours prior to sacrifice, rats were anesthetized with a mixture of ketamine (50 mg/kg) and xylazine (25 mg/kg) and eyes anesthetized locally using topical application of oxybuprocaine chlorhydrate . The hypertensive eye received an intravitreal injection (6 μl) of 0.5 mg Cholera toxin subunit β (CTB) conjugated to Alexa Fluor 594 (Molecular Probes, CA) while the control eye received a similar injection of CTB conjugated to Alexa Fluor 488 (Molecular Probes, CA) following earlier studies . After the 48 hour period, animals were deeply anesthetized with a lethal intraperitoneal injection of sodium pentobarbital (150 mg/kg) and perfused intracardially with warm (37°C) heparinized saline followed by 300 ml of Zamboni's fixative at 4°C. Brains were cryoprotected overnight in 30% sucrose/PBS and 50 μm coronal sections were taken through the midbrain and mounted on gelatin-coated slides. Retinas were dissected from the eye and vitreous removed after treatment with collagenase (400 units/ml) at 37°C for 15 minutes. Sections of optic nerve 2-3 mm proximal to the globe were isolated, post-fixed and prepared for embedding and semi-thin sectioning as previously described [66, 67].
Retinal ganglion cell number and CTB uptake
RGCs were immuno-labelled using antibodies against phosphorylated neurofilament-heavy (SMI31, Sternberger Monoclonal Incorporated, Baltimore, MD) following our published protocol . Confocal images (0.101 mm2) were captured on an Olympus FV-1000 inverted confocal microscope along the midline of each retinal quadrant at 1 to 4 mm from the optic disc. The number of SMI31-positive and CTB-positive RGCs per image were counted and RGC density calculated as cells per mm2.
A 2- to 3-mm section of optic nerve proximal to the globe was isolated, post-fixed for 1 hour in 4% paraformaldehyde, and prepared for embedding and sem-ithin sectioning . Sections were stained with para-phenylenediamine (PPD) and then photographed using 100× oil-immersion and differential interference contrast optics. Photomicrographs of each optic nerve section were collected as a montage using an Olympus Provis AX70 microscope with motorized X-Y-Z stage and a digital CCD video camera. Each montage was contrast and edge-enhanced using the ImagePro software package (Media Cybernetics, CA). An additional routine was used to identify and count each axon in the montage for which a myelin sheath could be identified. We used this information to calculate the mean local axon density for each section of nerve. This was multiplied by the cross-sectional area of the nerve section to obtain an estimate of the total number of axons as described .
Measurement of anterograde transport
Alternate sections of the brain containing superior colliculus were photographed using a Spot-RT camera on an Olympus AX-70 upright microscope and intensity of label was quantified using ImagePro (Media Cybernetics, Bethesda, MD) as described previously . After normalizing with respect to background, intensity was recorded based on mediolateral location in the section. Intensity calculations from alternate sections were then combined to form a colorimetric representation of CTB signal across the retinotopic collicular map. For each colliculus, we determined the fraction of intact retinotopic map, defined as the percent area with CTB signal ≥70% maximum.
Unless otherwise indicated, all data are presented as the mean ± the standard error of the mean (SEM). SigmaPlot for Windows version 11.0 (Systat Software, Inc,; Chicago, IL) was used to calculate p values in comparing data using either ANOVA or t tests for data meeting criteria for normalcy or using non-parametric rank statistics for data failing normalcy.
List of abbreviations
cholera toxin subunit β
cyclic adenosine monophosphate
glycogen synthase kinase-3; IOP; intraocular pressure
phosphatidylinositol 3 kinase
retinal ganglion cells.
Funding provided by an Allergan, Inc. Discovery Research Grant (DJC), the American Health Assistance Foundation (DJC), the Melza M. and Frank Theodore Barr Foundation through the Glaucoma Research Foundation (DJC), NIH EY017427 (DJC), and an Unrestricted Grant from Research to Prevent Blindness to the Vanderbilt University School of Medicine Department of Ophthalmology and Visual Sciences. Imaging supported through the Vanderbilt University Medical Center Cell Imaging Shared Resource core facility (CTSA grant UL1 RR024975 from NCRR/NIH) and the Vanderbilt Vision Research Center (P30EY008126).
- Nickells RW: From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol. 2007, 42: 278-287. 10.3129/can j ophthalmol.i07-036.PubMedView Article
- Quigley HA: Neuronal death in glaucoma. Prog Retin Eye Res. 1999, 18: 39-57. 10.1016/S1350-9462(98)00014-7.PubMedView Article
- Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M: Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002, 120: 1268-1279.PubMedView Article
- Investigators TA: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000, 130: 429-440. 10.1016/S0002-9394(00)00538-9.View Article
- Cheung W, Guo L, Cordeiro MF: Neuroprotection in glaucoma: drug-based approaches. Optom Vis Sci. 2008, 85: 406-416. 10.1097/OPX.0b013e31817841e5.PubMedPubMed CentralView Article
- Schober MS, Chidlow G, Wood JP, Casson RJ: Bioenergetic-based neuroprotection and glaucoma. Clin Experiment Ophthalmol. 2008, 36: 377-385. 10.1111/j.1442-9071.2008.01740.x.PubMedView Article
- Ogidigben M, Chu TC, Potter DE: Alpha-2 adrenoceptor mediated changes in aqueous dynamics: effect of pertussis toxin. Exp Eye Res. 1994, 58: 729-736. 10.1006/exer.1994.1070.PubMedView Article
- Toris CB, Camras CB, Yablonski ME: Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999, 128: 8-14. 10.1016/S0002-9394(99)00076-8.PubMedView Article
- Yoles E, Wheeler LA, Schwartz M: Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999, 40: 65-73.PubMed
- Vidal-Sanz M, Lafuente MP, Mayor S, de Imperial JM, Villegas-Perez MP: Retinal ganglion cell death induced by retinal ischemia: neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol. 2001, 45 (Suppl 3): S261-267. 10.1016/S0039-6257(01)00205-3. discussion S273-266PubMedView Article
- WoldeMussie E, Ruiz G, Wijono M, Wheeler LA: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001, 42: 2849-2855.PubMed
- Hernandez M, Urcola JH, Vecino E: Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res. 2008, 86: 798-806. 10.1016/j.exer.2008.02.008.PubMedView Article
- Ma K, Xu L, Zhang H, Zhang S, Pu M, Jonas JB: Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. Am J Ophthalmol. 2009, 147: 326-331. 10.1016/j.ajo.2008.08.005.PubMedView Article
- Gao H, Qiao X, Cantor LB, WuDunn D: Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002, 120: 797-803.PubMedView Article
- Dong CJ, Guo Y, Wheeler L, Hare WA: Alpha2 adrenergic receptor-mediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina. Invest Ophthalmol Vis Sci. 2007, 48: 1410-1415. 10.1167/iovs.06-0890.PubMedView Article
- Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008, 49: 4515-4522. 10.1167/iovs.08-2078.PubMedView Article
- Galanopoulos A, Goldberg I: Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin Ophthalmol. 2009, 3: 117-122.PubMedPubMed Central
- Aviles-Trigueros M, Mayor-Torroglosa S, Garcia-Aviles A, Lafuente MP, Rodriguez ME, Miralles de Imperial J, Villegas-Perez MP, Vidal-Sanz M: Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp Neurol. 2003, 184: 767-777. 10.1016/S0014-4886(03)00298-X.PubMedView Article
- Whitmore AV, Libby RT, John SW: Glaucoma: thinking in new ways-a role for autonomous axonal self-destruction and other compartmentalised processes?. Prog Retin Eye Res. 2005, 24: 639-662. 10.1016/j.preteyeres.2005.04.004.PubMedView Article
- Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, Steele MR, Vetter ML, Marsh-Armstrong N, Horner PJ: Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci. 2008, 28: 2735-2744. 10.1523/JNEUROSCI.4443-07.2008.PubMedView Article
- Crish SD, Sappington RM, Inman DM, Horner PJ, Calkins DJ: Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc Natl Acad Sci USA. 2010, 107: 5196-5201. 10.1073/pnas.0913141107.PubMedPubMed CentralView Article
- Jakobs TC, Libby RT, Ben Y, John SW, Masland RH: Retinal ganglion cell degeneration is topological but not cell type specific in DBA/2J mice. J Cell Biol. 2005, 171: 313-325. 10.1083/jcb.200506099.PubMedPubMed CentralView Article
- Schlamp CL, Li Y, Dietz JA, Janssen KT, Nickells RW: Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric. BMC Neurosci. 2006, 7: 66-10.1186/1471-2202-7-66.PubMedPubMed CentralView Article
- Soto I, Oglesby E, Buckingham BP, Son JL, Roberson ED, Steele MR, Inman DM, Vetter ML, Horner PJ, Marsh-Armstrong N: Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J Neurosci. 2008, 28: 548-561. 10.1523/JNEUROSCI.3714-07.2008.PubMedView Article
- Wax MB, Tezel G, Yang J, Peng G, Patil RV, Agarwal N, Sappington RM, Calkins DJ: Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci. 2008, 28: 12085-12096. 10.1523/JNEUROSCI.3200-08.2008.PubMedPubMed CentralView Article
- Danias J, Shen F, Goldblum D, Chen B, Ramos-Esteban J, Podos SM, Mittag T: Cytoarchitecture of the retinal ganglion cells in the rat. Invest Ophthalmol Vis Sci. 2002, 43: 587-594.PubMed
- Siminoff R, Schwassmann HO, Kruger L: An electrophysiological study of the visual projection to the superior colliculus of the rat. J Comp Neurol. 1966, 127: 435-444. 10.1002/cne.901270402.PubMedView Article
- Drager UC, Hubel DH: Topography of visual and somatosensory projections to mouse superior colliculus. J Neurophysiol. 1976, 39: 91-101.PubMed
- Lei Y, Garrahan N, Hermann B, Fautsch MP, Johnson DH, Hernandez MR, Boulton M, Morgan JE: Topography of neuron loss in the retinal ganglion cell layer in human glaucoma. Br J Ophthalmol. 2009, 93: 1676-1679. 10.1136/bjo.2009.159210.PubMedPubMed CentralView Article
- Soto I, Pease ME, Son JL, Shi X, Quigley HA, Marsh-Armstrong N: Retinal Ganglion Cell Loss in a Rat Ocular Hypertension Model is Sectorial and Involves Early Optic Nerve Axon Loss. Invest Ophthalmol Vis Sci. 2010, 10-5856. iovs
- Danylkova NO, Alcala SR, Pomeranz HD, McLoon LK: Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp Eye Res. 2007, 84: 293-301. 10.1016/j.exer.2006.10.002.PubMedView Article
- Mayor-Torroglosa S, De la Villa P, Rodriguez ME, Lopez-Herrera MP, Aviles-Trigueros M, Garcia-Aviles A, de Imperial JM, Villegas-Perez MP, Vidal-Sanz M: Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005, 46: 3825-3835. 10.1167/iovs.05-0392.PubMedView Article
- Ahmed FA, Hegazy K, Chaudhary P, Sharma SC: Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 2001, 913: 133-139. 10.1016/S0006-8993(01)02759-7.PubMedView Article
- Wheeler LA, Gil DW, WoldeMussie E: Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001, 45 (Suppl 3): S290-294. 10.1016/S0039-6257(01)00206-5. discussion S295-296PubMedView Article
- Kalapesi FB, Coroneo MT, Hill MA: Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005, 89: 758-763. 10.1136/bjo.2004.053025.PubMedPubMed CentralView Article
- Woldemussie E, Wijono M, Pow D: Localization of alpha 2 receptors in ocular tissues. Vis Neurosci. 2007, 24: 745-756. 10.1017/S0952523807070605.PubMedView Article
- Vidal L, Diaz F, Villena A, Moreno M, Campos JG, Perez de Vargas I: Reaction of Muller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res Bull. 2010, 82: 18-24. 10.1016/j.brainresbull.2010.02.011.PubMedView Article
- Knels L, Worm M, Wendel M, Roehlecke C, Kniep E, Funk RH: Effects of advanced glycation end products-inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UK-14,304. J Neurochem. 2008, 106: 1876-1887.PubMed
- Ozdemir G, Tolun FI, Gul M, Imrek S: Retinal oxidative stress induced by intraocular hypertension in rats may be ameliorated by brimonidine treatment and N-acetyl cysteine supplementation. J Glaucoma. 2009, 18: 662-665. 10.1097/IJG.0b013e31819c46b1.PubMedView Article
- Tatton WG, Chalmers-Redman RM, Sud A, Podos SM, Mittag TW: Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?. Surv Ophthalmol. 2001, 45 (Suppl 3): S277-283. 10.1016/S0039-6257(01)00207-7. discussuin S295-276PubMedView Article
- Aktas Z, Gurelik G, Akyurek N, Onol M, Hasanreisoglu B: Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model. Clin Experiment Ophthalmol. 2007, 35: 527-534. 10.1111/j.1442-9071.2007.01533.x.PubMedView Article
- Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler L: Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci. 2002, 19: 175-185. 10.1017/S0952523802191152.PubMedView Article
- Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Chauhan BC, Tremblay F, Kelly ME: Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci. 2002, 43: 2666-2676.PubMed
- Taraviras S, Olli-Lahdesmaki T, Lymperopoulos A, Charitonidou D, Mavroidis M, Kallio J, Scheinin M, Flordellis C: Subtype-specific neuronal differentiation of PC12 cells transfected with alpha2-adrenergic receptors. Eur J Cell Biol. 2002, 81: 363-374. 10.1078/0171-9335-00250.PubMedView Article
- Tolbert LM, Russell DS, Duman RS: Norepinephrine activates extracellular-regulated kinase in cortical neurons. Biol Psychiatry. 2003, 54: 983-993. 10.1016/S0006-3223(03)00346-9.PubMedView Article
- Klocker N, Kermer P, Weishaupt JH, Labes M, Ankerhold R, Bahr M: Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3'-kinase/protein kinase B signaling. J Neurosci. 2000, 20: 6962-6967.PubMed
- Nakazawa T, Shimura M, Tomita H, Akiyama H, Yoshioka Y, Kudou H, Tamai M: Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury. Curr Eye Res. 2003, 26: 55-63. 10.1076/ceyr.220.127.116.1154.PubMedView Article
- Maggirwar SB, Sarmiere PD, Dewhurst S, Freeman RS: Nerve growth factor-dependent activation of NF-kappaB contributes to survival of sympathetic neurons. J Neurosci. 1998, 18: 10356-10365.PubMed
- Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 1999, 96: 7421-7426. 10.1073/pnas.96.13.7421.PubMedPubMed CentralView Article
- Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999, 96: 857-868. 10.1016/S0092-8674(00)80595-4.PubMedView Article
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5.PubMedView Article
- del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997, 278: 687-689. 10.1126/science.278.5338.687.PubMedView Article
- Vander Heiden MG, Chandel NS, Li XX, Schumacker PT, Colombini M, Thompson CB: Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival. Proc Natl Acad Sci USA. 2000, 97: 4666-4671. 10.1073/pnas.090082297.PubMedPubMed CentralView Article
- Zhou H, Li XM, Meinkoth J, Pittman RN: Akt regulates cell survival and apoptosis at a postmitochondrial level. J Cell Biol. 2000, 151: 483-494. 10.1083/jcb.151.3.483.PubMedPubMed CentralView Article
- Goold RG, Owen R, Gordon-Weeks PR: Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J Cell Sci. 1999, 112 (Pt 19): 3373-3384.PubMed
- Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shiromizu T, Watanabe H, Inagaki N, Iwamatsu A, Hotani H, Kaibuchi K: CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol. 2002, 4: 583-591.PubMed
- Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H, Takenawa T, Kaibuchi K: CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol Cell Biol. 2005, 25: 9920-9935. 10.1128/MCB.25.22.9920-9935.2005.PubMedPubMed CentralView Article
- Kimura T, Watanabe H, Iwamatsu A, Kaibuchi K: Tubulin and CRMP-2 complex is transported via Kinesin-1. J Neurochem. 2005, 93: 1371-1382. 10.1111/j.1471-4159.2005.03063.x.PubMedView Article
- Bajaj NP, Miller CC: Phosphorylation of neurofilament heavy-chain side-arm fragments by cyclin-dependent kinase-5 and glycogen synthase kinase-3alpha in transfected cells. J Neurochem. 1997, 69: 737-743. 10.1046/j.1471-4159.1997.69020737.x.PubMedView Article
- Jung C, Lee S, Ortiz D, Zhu Q, Julien JP, Shea TB: The high and middle molecular weight neurofilament subunits regulate the association of neurofilaments with kinesin: inhibition by phosphorylation of the high molecular weight subunit. Brain Res Mol Brain Res. 2005, 141: 151-155. 10.1016/j.molbrainres.2005.08.009.PubMedView Article
- Cosker KE, Eickholt BJ: Phosphoinositide 3-kinase signalling events controlling axonal morphogenesis. Biochem Soc Trans. 2007, 35: 207-210. 10.1042/BST0350207.PubMedView Article
- Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001, 65: 391-426. 10.1016/S0301-0082(01)00011-9.PubMedView Article
- Hannigan G, Troussard AA, Dedhar S: Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005, 5: 51-63. 10.1038/nrc1524.PubMedView Article
- Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D: Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos. 2002, 30 (4): 421-9. 10.1124/dmd.30.4.421.PubMedView Article
- Drouyer E, Dkhissi-Benyahya O, Chiquet C, WoldeMussie E, Ruiz G, Wheeler LA, Denis P, Cooper HM: Glaucoma alters the circadian timing system. PLoS One. 2008, 3: e3931-10.1371/journal.pone.0003931.PubMedPubMed CentralView Article
- Inman DM, Sappington RM, Horner PJ, Calkins DJ: Quantitative correlation of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2006, 47: 986-996. 10.1167/iovs.05-0925.PubMedView Article
- Sappington RM, Carlson BJ, Crish SD, Calkins DJ: The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci. 2010, 51: 207-216. 10.1167/iovs.09-3947.PubMedPubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.